Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 3Completed 1

Sponsor Class

OTHER 12NIH 4INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1

Conditions

Carcinoma, Hepatocellular 3Thyroid Neoplasms 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Sorafenib × 90 days × Clear all
NCT02185560 2026-04-14

JPMS-DTC

Bayer

Active not recruiting
453 enrolled
Head & Neck

Thyroid Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Bristol-Myers Squibb

Phase 3 Active not recruiting
732 enrolled 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT03298451 2026-03-20

HIMALAYA

AstraZeneca

Phase 3 Active not recruiting
1,324 enrolled 31 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
344 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡